Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bharat H. Barai who wrote (445)	12/27/1997 4:44:00 AM
From: Bill Wexler	Read Replies (1) of 834

<<One of them showed positive trend but did not show statistically significant difference (I think that is the one you are referring to in your post). The present Product Licence Application (PLA) filed with FDA is NOT for Cardio Vascular indication but for Heparin induced Thrombocytopenia (HIT). This multi center trial showed highly statistical significat dfference (This trial data were presented at International Hematology meeting in Milan, Italy in June, 1997).>> Correct on count one. I completely disagree that the HIT trials showed statistically significant positive response. As far as the two new drugs are concerned. TXB's multi-year track record of delivering lots of promises but no product speaks for itself. Don't bet what you can't afford to lose.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next